

HORIZON PHARMACEUTICAL LLC  
Form 15-12G  
November 04, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**  
**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934.**

**000-25571**

**(Commission File Number)**

**HORIZON PHARMACEUTICAL LLC**  
**(Exact name of registrant as specified in its charter)**

**7 Hamilton Landing, Suite 100**

**Novato, CA 94949**

**(415) 408-6200**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Common Stock, \$0.001 par value per share**

**(Title of each class of securities covered by this Form)**

**None**

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)**

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)  
Rule 12g-4(a)(2)  
Rule 12h-3(b)(1)(i)  
Rule  
12h-3(b)(1)(ii)  
Rule 15d-6

Approximate number of holders of record as of the certification or notice date: 1

Pursuant to the requirements of the Securities Exchange Act of 1934, Horizon Pharmaceutical LLC (f/k/a Raptor Pharmaceutical Corp.) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: November 4, 2016

**HORIZON PHARMACEUTICAL LLC**

By: /s/ Paul W. Hoelscher

Name: Paul W. Hoelscher

Title: Executive Vice President, Chief Financial  
Officer

[Signature Page to Form 15]